BridgeMD
The One-Month DAPT with Ticagrelor In CABG PatieNts Trial (ODIN)
EU CTIS ID: 2023-506613-22-00
What this study is testing
To compare the effect of ticagrelor in addition to ASA versus ASA alone for 1 month on the 1-year incidence of ischemic events and graft failure among patients undergoing CABG for SIHD.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥18 years
- Elective first-time CABG with use of ≥1 saphenous vein graft
- Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years
- Chronic coronary disease
You likely can't join if
- Any indication for dual antiplatelet therapy, including •Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI) •Recent PCI requiring continuation of dual antiplatelet therapy after CABG
- Inability to undergo coronary computed tomographic angiography (CCTA)
- Participating in another investigational device or drug study within five times the half-life of the drug/metabolites
- Women of childbearing potential
- Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis
- Current or anticipated use of oral anticoagulation
See the full eligibility criteria
- Age ≥18 years
- Elective first-time CABG with use of ≥1 saphenous vein graft
- Ability to sign informed consent and comply with all study procedures, including follow-up for at least 5 years
- Chronic coronary disease
- Any indication for dual antiplatelet therapy, including •Acute/recent (within 1 year) ACS (NSTE-ACS or STEMI) •Recent PCI requiring continuation of dual antiplatelet therapy after CABG
- Inability to undergo coronary computed tomographic angiography (CCTA)
- Participating in another investigational device or drug study within five times the half-life of the drug/metabolites
- Women of childbearing potential
- Any major perioperative complication including, but not limited to, stroke, TIA, MI, CABG-related bleeding (BARC type 4), sepsis
- Current or anticipated use of oral anticoagulation
- Paroxysmal, persistent or permanent atrial fibrillation
- Any concomitant cardiac or non-cardiac procedure
- Planned cardiac or non-cardiac surgery within one year
- Preoperative end-organ dysfunction (dialysis, moderate to severe liver failure, respiratory failure), cancer or other non-cardiac comorbidity with a life expectancy <5 years
- Inability to use the saphenous vein
- Contraindications to the use of aspirin
- Contraindications to the use of ticagrelor, including •Known hypersensitivity to ticagrelor •Active pathological bleeding (including, but not limited to gastrointestinal or intracranial bleeding) •History of intracranial hemorrhage •Concomitant therapy with strong CYP3A4 inhibitors (eg ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir)
The study team makes the final eligibility decision.
Where it's taking place
- United States
- China
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; China; Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.